Pharmacogenetics: From Bench to Byte— An Update of Guidelines

@article{Swen2011PharmacogeneticsFB,
  title={Pharmacogenetics: From Bench to Byte— An Update of Guidelines},
  author={J. Swen and M. Nijenhuis and A. Boer and L. Grandia and A. Maitland‐van der Zee and H. Mulder and G. Rongen and R. Schaik and T. Schalekamp and D. Touw and J. Weide and B. Wilffert and V.H.M. Deneer and H. Guchelaar},
  journal={Clinical Pharmacology & Therapeutics},
  year={2011},
  volume={89}
}
  • J. Swen, M. Nijenhuis, +11 authors H. Guchelaar
  • Published 2011
  • Medicine
  • Clinical Pharmacology & Therapeutics
    • Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics‐based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine‐S… CONTINUE READING
    View on Wiley
    ascpt.onlinelibrary.wiley.com
    707 Citations
    Highly Influencial Citations
    39
    Background Citations
    182
    Methods Citations
    61
    Results Citations
    7

    Topics from this paper

    Explore Further: Topics Discussed in This Paper

      Paper Mentions

      Blog Post
      ABACAVIR
      New Drug Approvals
      4 June 2019
      707 Citations
      Citation Type

      Citation Type

      Pharmacogenetics of anti-cancer drugs: State of the art and implementation - recommendations of the French National Network of Pharmacogenetics.
      • 13
      Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
      • 140
      • PDF
      Cytochrome P450 genotype‐guided drug therapies: An update on current states
      • 13
      Pharmacogenetics implementation in the clinics: information and guidelines for germline variants
      • 5
      • Highly Influenced
      • PDF
      Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update
      • 219
      • PDF
      Pharmacogenomics guidelines: Current status and future development
      • 1
      Evidence based drug dosing and pharmacotherapeutic recommendations per genotype.
      • 5
      Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel
      • 26
      Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain
      • 19
      • PDF
      The role of ADME pharmacogenomics in early clinical trials: perspective of the Industry Pharmacogenomics Working Group (I-PWG).
      • 12

      References

      SHOWING 1-10 OF 14 REFERENCES
      Pharmacogenetics: From Bench to Byte
      • 175
      • PDF
      Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.
      • 142
      • PDF
      CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants:
a first step towards subpopulation‐specific dosages
      • 406
      Clinically Available Pharmacogenomics Tests
      • 64
      Role of warfarin pharmacogenetic testing in clinical practice.
      • 52
      • PDF
      A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.
      • 669
      • PDF
      Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
      • 1,329
      • PDF
      Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
      • 1,047
      Identification of the gene for vitamin K epoxide reductase
      • 678
      Relative Impact of Genotype and Enzyme Induction on the Metabolic Capacity of CYP2C9 in Healthy Volunteers
      • 35